254 related articles for article (PubMed ID: 30962046)
1. Pathophysiology and Future Therapeutic Perspectives for Resolving Fibrosis in Peyronie's Disease.
Milenkovic U; Ilg MM; Cellek S; Albersen M
Sex Med Rev; 2019 Oct; 7(4):679-689. PubMed ID: 30962046
[TBL] [Abstract][Full Text] [Related]
2. Antifibrotic Synergy Between Phosphodiesterase Type 5 Inhibitors and Selective Oestrogen Receptor Modulators in Peyronie's Disease Models.
Ilg MM; Mateus M; Stebbeds WJ; Milenkovic U; Christopher N; Muneer A; Albersen M; Ralph DJ; Cellek S
Eur Urol; 2019 Feb; 75(2):329-340. PubMed ID: 30344087
[TBL] [Abstract][Full Text] [Related]
3. Review of Management Options for Patients With Atypical Peyronie's Disease.
Yafi FA; Hatzichristodoulou G; DeLay KJ; Hellstrom WJ
Sex Med Rev; 2017 Apr; 5(2):211-221. PubMed ID: 27544298
[TBL] [Abstract][Full Text] [Related]
4. Phosphodiesterase Type 5 Inhibitors and Selective Estrogen Receptor Modulators Can Prevent But Not Reverse Myofibroblast Transformation in Peyronie's Disease.
Ilg MM; Stafford SJ; Mateus M; Bustin SA; Carpenter MJ; Muneer A; Bivalacqua TJ; Ralph DJ; Cellek S
J Sex Med; 2020 Oct; 17(10):1848-1864. PubMed ID: 32771352
[TBL] [Abstract][Full Text] [Related]
5. What role do pharmaceuticals play in the treatment of Peyronie's disease and is there a need for new emerging drugs?
Milenkovic U; Ilg M; Cellek S; Albersen M
Expert Opin Emerg Drugs; 2019 Mar; 24(1):1-4. PubMed ID: 30845848
[TBL] [Abstract][Full Text] [Related]
6. Understanding the Role of Adenosine Receptors in the Myofibroblast Transformation in Peyronie's Disease.
Mateus M; Ilg MM; Stebbeds WJ; Christopher N; Muneer A; Ralph DJ; Cellek S
J Sex Med; 2018 Jul; 15(7):947-957. PubMed ID: 29891411
[TBL] [Abstract][Full Text] [Related]
7. A review of inflammation and fibrosis: implications for the pathogenesis of Peyronie's disease.
Patel DP; Christensen MB; Hotaling JM; Pastuszak AW
World J Urol; 2020 Feb; 38(2):253-261. PubMed ID: 31190155
[TBL] [Abstract][Full Text] [Related]
8. Peyronie's disease.
Pryor J; Akkus E; Alter G; Jordan G; Lebret T; Levine L; Mulhall J; Perovic S; Ralph D; Stackl W
J Sex Med; 2004 Jul; 1(1):110-5. PubMed ID: 16422991
[TBL] [Abstract][Full Text] [Related]
9. Collagenase Clostridium histolyticum in the Treatment of Peyronie's Disease-A Review of the Literature and a New Modified Protocol.
Abdel Raheem A; Johnson M; Abdel-Raheem T; Capece M; Ralph D
Sex Med Rev; 2017 Oct; 5(4):529-535. PubMed ID: 28874327
[TBL] [Abstract][Full Text] [Related]
10. Management of Peyronie's disease--a review.
Tunuguntla HS
World J Urol; 2001 Aug; 19(4):244-50. PubMed ID: 11550782
[TBL] [Abstract][Full Text] [Related]
11. Contemporary Review of Grafting Techniques for the Surgical Treatment of Peyronie's Disease.
Hatzichristodoulou G; Osmonov D; Kübler H; Hellstrom WJG; Yafi FA
Sex Med Rev; 2017 Oct; 5(4):544-552. PubMed ID: 28258933
[TBL] [Abstract][Full Text] [Related]
12. Peyronie's disease: epidemiology, diagnosis, and management.
Miner MM; Seftel AD
Curr Med Res Opin; 2014 Jan; 30(1):113-20. PubMed ID: 24040888
[TBL] [Abstract][Full Text] [Related]
13. Adipose tissue-derived stem cell therapy for prevention and treatment of erectile dysfunction in a rat model of Peyronie's disease.
Gokce A; Abd Elmageed ZY; Lasker GF; Bouljihad M; Kim H; Trost LW; Kadowitz PJ; Abdel-Mageed AB; Sikka SC; Hellstrom WJ
Andrology; 2014 Mar; 2(2):244-51. PubMed ID: 24574095
[TBL] [Abstract][Full Text] [Related]
14. The Impact of Peyronie's Disease on the Patient: Gaps in Our Current Understanding.
Goldstein I; Hartzell R; Shabsigh R
J Sex Marital Ther; 2016; 42(2):178-90. PubMed ID: 25405853
[TBL] [Abstract][Full Text] [Related]
15. Peyronie's disease: review and recent advances.
Langston JP; Carson CC
Maturitas; 2014 Aug; 78(4):341-3. PubMed ID: 24984940
[TBL] [Abstract][Full Text] [Related]
16. Penile trauma: an etiologic factor in Peyronie's disease and erectile dysfunction.
Jarow JP; Lowe FC
J Urol; 1997 Oct; 158(4):1388-90. PubMed ID: 9302127
[TBL] [Abstract][Full Text] [Related]
17. Temporal gene signature of myofibroblast transformation in Peyronie's disease: first insights into the molecular mechanisms of irreversibility.
Ilg MM; Harding S; Lapthorn AR; Kirvell S; Ralph DJ; Bustin SA; Ball G; Cellek S
J Sex Med; 2024 Mar; 21(4):278-287. PubMed ID: 38383071
[TBL] [Abstract][Full Text] [Related]
18. Penile Doppler sonographic and clinical characteristics in Peyronie's disease and/or erectile dysfunction: an analysis of 1500 men with male sexual dysfunction.
Chung E; Yan H; De Young L; Brock GB
BJU Int; 2012 Oct; 110(8):1201-5. PubMed ID: 22313546
[TBL] [Abstract][Full Text] [Related]
19. Factors Associated With Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients With Peyronie Disease.
Serefoglu EC; Smith TM; Kaufman GJ; Liu G; Yafi FA; Hellstrom WJG
Urology; 2017 Sep; 107():155-160. PubMed ID: 28554517
[TBL] [Abstract][Full Text] [Related]
20. Fibroproliferative disorders and diabetes: Understanding the pathophysiologic relationship between Peyronie's disease, Dupuytren disease and diabetes.
Gelbard MK; Rosenbloom J
Endocrinol Diabetes Metab; 2021 Apr; 4(2):e00195. PubMed ID: 33855203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
